Illustration showing how miniature artificial protocells loaded with anti-microRNA-223 cargo can reprogram cancer-associated macrophages in larval and adult zebrafish leading them to be more pro-inflammatory and thus able to drive melanoma shrinkage
CREDIT: Paco Lopez Cuevas
Discovery demonstrates a new way to clear early stage pre-cancerous and even late-stage tumour cells
A new way of reprogramming our immune cells to shrink or kill off cancer cells has been shown to work in the otherwise hard to treat and devastating skin cancer, melanoma. The University of Bristol-led discovery, published in Advanced Science today [31 October], demonstrates a new way to clear early stage pre-cancerous and even late-stage tumour cells.
Using miniature artificial capsules called protocells designed to deploy reprogramming cargoes that are taken up by inflammatory cells (white blood cells), the scientists show they were able to transform these cells into a state that makes them more effective at slowing down the growth and killing of melanoma cells. They showed that this was possible for both animal and human immune cells.
The study is the first to test the capacity of a protocell to deliver cargoes for reprogramming immune cells and offers a promising novel target for the development of cancer immunotherapies.
Paul Martin, Professor of Cell Biology in the School of Biochemistry at the University of Bristol and one of the study’s lead authors explained what happens when our immune system comes into contact with cancer cells: “Our immune cells have a surveillance capacity which enables them to detect pre-cancerous cells arising at any tissue site in the body. However, when immune cells encounter cancer cells they are often subverted by the cancer cells and instead tend to nourish them and encourage cancer progression. We wanted to test whether it might be possible to reprogramme our immune system to kill these cells rather than nurture them.”
First, the team tested the proof of concept in zebrafish larvae which are used due to their translucency, allowing researchers to watch inflammatory immune cells interact with cancer cells in ways not possible in our own tissues.
Protocells loaded with anti-miR223 molecules that bind to and interfere with signalling machinery in the inflammatory immune cells and work by effectively prolonging their pro-inflammatory state, were shown to drive altered immune cell-cancer cell interactions, slowing the growth of cancerous cells and driving increased tumour cell death in the larvae.
To find out whether this approach might be upscaled as a feasible therapeutic strategy for shrinking larger, more established, and growing cancers, the experiment was repeated in adult fish with tailfin melanomas, showing this approach significantly inhibited melanoma cell growth.
To fully investigate the feasibility of using protocells to deliver ‘reprogramming’ anti-miR223 cargoes in humans, the experiment was conducted again using an in vitro assay with primary human immune cells from the Toye lab, also in Bristol’s School of Biochemistry. Results from this experiment demonstrated that the protocells were able to effectively deliver and reprogramme human immune cells toward a more persistent pro-inflammatory and potentially anti-cancer state.
Professor Stephen Mann from Bristol’s School of Chemistry and the Max Planck Bristol Centre for Minimal Biology added: “Our results highlight the therapeutic benefits of harnessing host immunity to eradicate cancers and demonstrate the feasibility of using protocells to deliver cargoes for reprogramming innate immune cells. While our experiments in zebrafish are early pre-clinical studies, our results indicate that the same is possible for human immune cells, at least in vitro, and can be similarly reprogrammed to supress cancer growth.”
Original Article: Reprogramming of immune cells shown to fight off melanoma
More from: University of Bristol
The Latest Updates from Bing News
Go deeper with Bing News on:
Reprogramming immune cells
- UF Health scientists make breakthrough in possible cancer treatment
Small clinical trials have shown the individually tailored mRNA vaccines can produce a very rapid immune system response.
- Car T-Cell Therapy
Car T-Cell Therapy is a type of cellular immunotherapy used for patients with certain types of leukemias and lymphomas, as well as multiple myeloma. It uses the patient’s own immune system cells to ...
- ‘Onion structure’ vaccine triggers immune system against glioblastoma
Researchers from the University of Florida have developed a novel mRNA cancer vaccine that aims to reprogram the immune system to target and attack cancer cells effectively. The study led by Elias ...
- Cancer Vaccine Triggers Fierce Immune Response to Fight Malignant Brain Tumors in Human Patients
In the first human trial, an mRNA cancer vaccine at the University of Florida triggered immune systems to fiercely attack glioblastoma.
- Master regulator of inflammation found — and it's in the brain stem
Research in mice suggests that specific neurons within the brain stem act like the dial on a thermostat — fine-tuning inflammation as and when required.
Go deeper with Bing News on:
Inhibiting melanoma cell growth
- Merck Ends Keytruda Combo Melanoma Study Due to Futility
Merck (NYSE: MRK) announced that it is discontinuing a cohort of the phase III study evaluating a co-formulation of its blockbuster PD-L1 inhibitor, Keytruda plus vibostolimab, its investigational ...
- Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
Merck MRK announced that it is discontinuing a cohort of the phase III study evaluating a co-formulation of its blockbuster PD-L1 inhibitor, Keytruda plus vibostolimab, its investigational anti-TIGIT ...
- Merkel Cell Carcinoma Treatment Market To Reach USD 4.3 Billion By 2032 | DataHorizzon Research
The merkel cell carcinoma treatment market size was valued at USD 3.1 Billion in 2023 and is expected to reach a market size of USD 4.3 Billion by 2032 at a CAGR of 3.9%.Fort Collins, Colorado, May 11 ...
- Acral Lentiginous Melanoma Market Predicted to Hit USD 122.3 Million by 2033: CAGR 3.80% | Marketresearch.biz
Marketresearch.biz reports that the The Global Acral Lentiginous Melanoma Market size is expected to be worth around USD 122.3 Million by 2033, from USD 85 Million in 2023, growing at a CAGR of 3.80% ...
- Scientists discover how deadly skin cancer evades the human immune system
In melanoma cells, NGF and TrkA diminish the production of signals that typically attract immune cells to the tumour site. Furthermore, they also inhibit the activation of immune cells tasked with ...